HDAC6 may represent an attractive target for the therapy of α-Synucleinopathies, however, the effects of its enzymatic (deacetylation activity) or non-enzymatic activity (binding to ubiquitin) on α-Syn inclusion formation are still not conclusive. Here, HDAC6 is linked to synucleinopathy.